Overview
Announcements

Ordinary Re-Weighting | RBC Biotech Opportunities Index | Effective Date 2nd April 2024

RBC Biotech Opportunities Index:

In the ordinary re-weighting, the following composition will be implemented effective open 2nd April 2024:

ABBVIE INC
ALNYLAM PHARMACEUTICALS INC
BIOGEN INC
BIOMARIN PHARMACEUTICAL INC
GILEAD SCIENCES INC
INCYTE CORP
INTRA-CELLULAR THERAPIES INC
ELI LILLY & CO
SAREPTA THERAPEUTICS INC